Postoperative Radiotherapy Contributes to the Survival Benefit of Breast-Conserving Therapy over Mastectomy

Table 2

. The multivariate analysis of risk factors for RFS in the whole cohort and in patients without RNI of the matched cohort.

Variables	Whole cohort			Patients without RNI of the matched cohort
	HR	95% CI	value	HR	95% CI	value
Age (years)	1.002	0.989–1.016	>0.05	1.008	0.981–1.036	>0.05
Grade
I	1.0			1.0
II	3.1	0.7–12.7	>0.05	—	—	>0.05
III	4.9	1.2–20.6	<0.05	—	—	>0.05
Molecular subtype
Luminal A-like	1.0			1.0
Luminal B-like (HER2-negative)	1.7	1.1–2.7	<0.05	1.3	0.5–3.2	>0.05
Luminal B-like (HER2-positive)	0.9	0.4–1.7	>0.05	0.6	0.1–3.1	>0.05
HER2-positive (nonluminal)	0.9	0.4–2.0	>0.05	0.4	0.0–3.7	>0.05
TNBC	1.6	0.8–3.6	>0.05	0.6	0.1–3.5	>0.05
Adjuvant chemotherapy
No	1.0			1.0
Yes	1.1	0.7–1.7	>0.05	1.4	0.6–3.2	>0.05
Endocrine therapy
No	1.0			1.0
Yes	0.8	0.4–1.5	>0.05	0.5	0.1–2.1	>0.05
Treatment
BCT	1.0			1.0
Mastectomy	2.8	1.7–4.7	<0.05	2.3	1.2–4.5	<0.05

TNBC, triple-negative breast cancer; BCT, breast-conserving therapy.